News
Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children – Results of the TERIKIDS Study
Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.
Cost-Effectiveness of Eletriptan in Acute Migraine Treatment
Even in a market dominated by generics, eletriptan 40 mg is among the most clinically effective and…
Doc. Petr Dulíček: Physical activity in hemophiliacs? Today it is a reality - just don't be afraid!
Thanks to modern treatment, the lives of hemophiliacs are becoming more active. Patients today can…
Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to...
Tofacitinib Helps Restore Intestinal Epithelial Barrier
The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the treatment of…
Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis – Interim Results of the OPAL Balance Study
Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the…
Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice – Results of the STAR-RA Study
Recent results from the ORAL Surveillance clinical trial have raised concerns about the…
Maintenance of Remission with Tofacitinib in Patients with UC – Results of the OCTAVE Open Study
Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional…
Indication of Bilastine in Specific Patient Groups − Practical Tips for Clinical Practice
Bilastine is a non-sedating H1-antihistamine, which is very well tolerated by patients. It can be…
Bilastine in the treatment of allergic rhinitis – meta-analysis shows advantage of lower somnolence
A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine…